Baricitinib (Olumiant) for Severe Alopecia Areata Treatment Recommendations

CADTH recommends public drug plans reimburse Olumiant for adults with severe alopecia areata (AA) under specific conditions, including at least 50% scalp hair loss and an AA episode lasting 6 months to 8 years. It must be prescribed by a dermatologist with expertise in severe AA, and the cost should be reduced. Olumiant should not be combined with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants. Initial reimbursement is for 36 weeks, with potential extensions every 12 months if improvements continue.